# BrightEdge Fund

> BrightEdge Fund is a VC fund in Atlanta backing Biotechnology and Health Care. See 34 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Atlanta, United States
- Total investments: 34
- Last investment: Dec 2025
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/brightedgefund
- Website: https://brightedgefund.org/

BrightEdge Fund is a VC fund in Atlanta focused on Biotechnology and Health Care. BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapiesand technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer.

## Contacts

5 contacts available for BrightEdge Fund. Shizune tracks 1 team members at BrightEdge Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brightedge-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.8M–$15M |
| Series A | $14M–$203M |
| Series B | $27M–$160M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 14 | 41% |
| Health Care | 13 | 38% |
| Therapeutics | 9 | 26% |
| Medical | 6 | 18% |
| Health Diagnostics | 4 | 12% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 18% |
| Series A | 6 | 18% |
| Series B | 6 | 18% |
| Pre-Seed | 2 | 6% |
| Series C | 2 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 50% |
| Israel | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lucas de Breed | Director | 1 | https://shizune.co/investors/profile/lucas-de-breed |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Paradigm | Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $78M | Series B | Dec 04, 2025 |  |
| Alpheus Medical | Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). | $52M | Series B | May 15, 2025 |  |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M | Series B | Feb 04, 2025 |  |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M |  | Jan 01, 2025 |  |
| Nine Diagnostics | Functional Precision Medicine by Design. A faster path to the most effective treatment. |  | Pre-Seed | Oct 01, 2024 |  |
| Clasp Therapeutics | Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M | Series A | Mar 20, 2024 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M |  | Feb 15, 2024 |  |
| Modifi Bio | Modifi Biosciences is a direct DNA modification developing novel cancer therapeutics. The company's strategy for combating cancer centers around modifying tumor DNA in a way that renders cancer cells irreparable while preserving the integrity of healthy cells. This unique approach empowers researchers to disrupt traditional oncology drugdevelopment methods. | $4.3M | Seed | Oct 16, 2023 |  |
| Thatch | Thatch helps businesses give great healthcare to their employees. | $5.6M | Seed | Feb 15, 2023 |  |
| Thatch | Thatch helps businesses give great healthcare to their employees. | $400K | Pre-Seed | Feb 15, 2023 |  |

10 of 34 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 8 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 6 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 6 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 5 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Wellness Investors in Israel](https://shizune.co/investors/wellness-investors-israel)
- [Wellness VC Funds in Israel](https://shizune.co/investors/wellness-vc-funds-israel)
- [Fitness VC Funds in Middle East](https://shizune.co/investors/fitness-vc-funds-middle-east)
- [Fitness Investors in Israel](https://shizune.co/investors/fitness-investors-israel)
- [Sports VC Funds in Israel](https://shizune.co/investors/sports-vc-funds-israel)
- [Fitness VC Funds in Israel](https://shizune.co/investors/fitness-vc-funds-israel)

## FAQ

### What does BrightEdge Fund invest in?

BrightEdge Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 34 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BrightEdge Fund's check size?

BrightEdge Fund typically joins rounds of $1.8M–$15M at Seed, $14M–$203M at Series A and $27M–$160M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BrightEdge Fund participates in.

### How do I contact BrightEdge Fund?

Public channels for BrightEdge Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BrightEdge Fund?

The team at BrightEdge Fund includes Lucas de Breed (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co